Clear cell renal carcinoma essentially requires CDKL3 for oncogenesis

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Clear cell renal cell carcinoma (ccRCC) is a prevalent kidney cancer with increasing incidence and mortality.
• Hyperactivation of hypoxia-inducible factor (HIF) and mammalian target of rapamycin (mTOR) signaling pathways are hallmarks of ccRCC.
• The role of CDKL3, a Ser/Thr kinase, in ccRCC pathogenesis is underappreciated.

Purpose of the Study:

• To investigate the role of CDKL3 in the initiation and progression of ccRCC using a spontaneous ccRCC model.
• To elucidate the molecular mechanism by which CDKL3 contributes to ccRCC development.
• To explore the clinical relevance of CDKL3 in ccRCC.

Main Methods:

• Utilized a spontaneous ccRCC mouse model to study CDKL3 function.
• Assessed the impact of CDKL3 ablation on ccRCC formation and growth in vivo.
• Investigated the interaction between CDKL3, Akt, and mTOR signaling pathways.
• Examined clinical correlations to support the oncogenic role of CDKL3.

Main Results:

• Ablation of CDKL3 prevented ccRCC formation and growth without affecting normal kidney function.
• CDKL3 deficiency abrogated Akt-mTOR hyperactivity and reduced HIF signaling in ccRCC.
• CDKL3 acts as an adaptor protein, potentiating mTORC2-dependent Akt activation independently of its kinase activity.
• A positive feedback loop exists where mTORC2 phosphorylates and stabilizes CDKL3, sustaining Akt-mTOR overactivation.

Conclusions:

• CDKL3 plays a critical, indispensable role in the initiation and progression of ccRCC.
• The CDKL3-mediated Akt-mTOR axis is crucial for ccRCC pathogenesis.
• Targeting CDKL3 presents a potential therapeutic strategy for ccRCC by disrupting the Akt-mTOR pathway.